ATLANTA--(BUSINESS WIRE)-- Inhibitex, Inc. (Nasdaq: INHX), today announced that Russell H. Plumb, president and chief executive officer, will present an overview of the company and its pipeline of differentiated antiviral compounds at the Canaccord Genuity Growth Conference on Tuesday, August 9, 2011 at 3:30 p.m. EDT. The conference is being held at The Intercontinental Hotel in Boston, Massachusetts. The presentation will be simultaneously webcast and can be accessed by visiting the Investors section of the Inhibitex website at www.inhibitex.com. Shortly following the live webcast a replay will also be available on the Company website.
About Inhibitex
Inhibitex, Inc. is a biopharmaceutical company focused on developing products to prevent and treat serious infectious diseases. The Company’s clinical-stage pipeline currently includes two Phase 2 development programs; INX-189, a nucleotide polymerase inhibitor in development for the treatment of chronic hepatitis C infections and FV-100, a nucleoside analogue in development for the treatment of shingles-associated pain. The Company also has additional HCV nucleotide polymerase inhibitors in preclinical development and has licensed the use of its proprietary MSCRAMM® protein platform to Pfizer for the development of a staphylococcal vaccine, which is currently being evaluated in a Phase 1 clinical trial. For additional information about the Company, please visit www.inhibitex.com.
Inhibitex® and MSCRAMM® are registered trademarks of Inhibitex, Inc.
CONTACT:
Inhibitex, Inc.
Russell H. Plumb, 678-746-1136
Chief Executive Officer
[email protected]
or
The Trout Group
Lee M. Stern, 646-378-2922
[email protected]
KEYWORDS: United States North America Georgia Massachusetts
INDUSTRY KEYWORDS: Health Biotechnology Clinical Trials Hospitals Infectious Diseases Pharmaceutical Research Science
MEDIA:
| Logo |